GTC Biotherapeutics (fka GTCB)

[mouton29]

<<dose-ranging, a term generally used for phase-1 trials where the maximum dose has not yet been established>>

A quick search on clinicaltrials.gov shows 87 phase I studies, 296 phase II studies, and even 54 phase III studies describing themselves as "dose ranging."

Putting aside the semantics, I think you are saying that sometimes you do a study to determine the maximum dose before material side effects appear, whereas in other studies, you try to find the best (most therapeutic) dose -- which is not always the maximum tolerated dose. That distinction certainly makes sense, and the Leo trial is in the latter class.